Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Satellos Bioscience (MSCLF)
OTHER OTC:MSCLF
Holding MSCLF?
Track your performance easily
MSCLF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.22 - $0.58
Previous Close$0.38
Volume21.04K
Average Volume (3M)20.43K
Market Cap
$38.91M
Enterprise Value$14.48M
Total Cash (Recent Filing)C$33.17M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Nov 20, 2024EPS Estimate
-$0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding112,791,658
10 Day Avg. Volume32,063
30 Day Avg. Volume20,434
Standard Deviation0.24
R-Squared0.12
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.23
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$0.88Price Target Upside130.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Satellos Bioscience News
PremiumCompany Announcements
Satellos Bioscience Begins Landmark Muscle Regeneration Trial
PremiumCompany Announcements
Satellos Bioscience to Present at Key Investor Events
PremiumCompany Announcements
Satellos Bioscience Advances DMD Treatment into Clinical Trials
PremiumCompany Announcements
Satellos Bioscience Reports Positive Drug Study Results
PremiumCompany Announcements
Satellos’ DMD Drug Earns Key FDA Designations
PremiumCompany Announcements
Satellos Bioscience’s DMD Drug Earns Key FDA DesignationsPremiumCompany Announcements
Satellos Bioscience Advances to Clinical Trials with SAT-3247
Options Prices
Currently, No data available
---
Ownership Overview
41.04% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
58.96% Public Companies and
Individual Investors
MSCLF FAQ
What was Satellos Bioscience’s price range in the past 12 months?
Satellos Bioscience lowest stock price was $0.22 and its highest was $0.58 in the past 12 months.
What is Satellos Bioscience’s market cap?
Currently, no data Available
When is Satellos Bioscience’s upcoming earnings report date?
Satellos Bioscience’s upcoming earnings report date is Nov 20, 2024 which is in 61 days.
How were Satellos Bioscience’s earnings last quarter?
Satellos Bioscience released its earnings results on Aug 12, 2024. The company reported -$0.037 earnings per share for the quarter, beating the consensus estimate of -$0.044 by $0.007.
Is Satellos Bioscience overvalued?
According to Wall Street analysts Satellos Bioscience’s price is currently Undervalued.
Does Satellos Bioscience pay dividends?
Satellos Bioscience does not currently pay dividends.
What is Satellos Bioscience’s EPS estimate?
Satellos Bioscience’s EPS estimate is -$0.04.
How many shares outstanding does Satellos Bioscience have?
Satellos Bioscience has 112,858,030 shares outstanding.
What happened to Satellos Bioscience’s price movement after its last earnings report?
Satellos Bioscience reported an EPS of -$0.037 in its last earnings report, beating expectations of -$0.044. Following the earnings report the stock price went up 3.03%.
Which hedge fund is a major shareholder of Satellos Bioscience?
Currently, no hedge funds are holding shares in MSCLF
---
Satellos Bioscience Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$0.88 (130.97% Upside)
$0.88 (130.97% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.35%
12-Months-Change
Fundamentals
Return on Equity
-58.12%
Trailing 12-Months
Asset Growth
-39.52%
Trailing 12-Months
Company Description
Satellos Bioscience
iCo Therapeutics, Inc. engages in the business of identification, development and commercialization of drug candidates for the treatment of sight- and life-threatening diseases. Its products include iCo-008 and oral AmpB delivery system. The company was founded by Andrew J. Rae, John G. Clement and William John Meekison on February 15, 2005 and is headquartered in Vancouver, CA.
---
MSCLF Stock 12 Month Forecast
Average Price Target
$0.88
▲(130.97% Upside)
Technical Analysis
Brainstorm Cell Therapeutics
―
Plus Therapeutics
―
Cellectar Biosciences
―
Gilead Sciences
―
Best Analysts Covering MSCLF
1 Year
1 Year Success Rate
3/3 ratings generated profit
1 Year Average Return
+4.30%
reiterated a buy rating 2 days ago
Copying Arthur He CFA's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +4.30% per trade.
---